Which peptides are studied for gut and digestive conditions?
Short answer
9 profiles here are grouped under “Gut and digestion”: 4 FDA-approved, 3 in clinical trials and 2 not FDA-approved.
Each entry below quotes its profile and links to the full answer there.
FDA-approved 4
In clinical trials 3
Not FDA-approved 2
Not an FDA-approved drug16
Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.16,17,18
Is BPC-157 FDA-approved? · BPC-157 vs TB-500 · BPC-157 vs KPV
Unapproved new drug in cited enforcement record19
Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.14,20
Is ipamorelin FDA-approved? · CJC-1295 vs Ipamorelin · Ipamorelin vs Sermorelin
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1LINZESS (linaclotide) capsule · SPL version 39 · published 2026-06-01 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA202811 · original submission status AP · 2012-08-30 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3TRULANCE (plecanatide) tablet · SPL version 15 · published 2024-04-05 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 4Drugs@FDA application NDA208745 · original submission status AP · 2017-01-19 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5CHIRHOSTIM (human secretin) for injection · SPL version 20251008 · published 2025-11-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 6Drugs@FDA: CHIRHOSTIM (secretin synthetic human), NDA 021256 · original approval April 9, 2004 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 7GATTEX (teduglutide) kit · SPL version 20 · published 2025-09-18 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 8Drugs@FDA: GATTEX (teduglutide), NDA 203441 · original approval December 21, 2012 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 9Apraglutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 10STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure (2026) · PMID 42692160 ↗
Clinical Gastroenterology and Hepatology · Official source · Source checked November 15, 2026
- 11Glepaglutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 12Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial (2025) · PMID 39708985 ↗
Gastroenterology · Official source · Source checked November 15, 2026
- 13Larazotide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 14Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 15Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial (2015) · PMID 25683116 ↗
Gastroenterology · Official source · Source checked November 15, 2026
- 16FDA briefing document for BPC-157-related bulk drug substances ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 17Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 18HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 19Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 20FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026